Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The prevalence of calcific aortic valve disease is increasing with aging of the population. Current treatment options for advanced or symptomatic aortic stenosis are limited to traditional surgical or percutaneous aortic valve replacement. Medical therapies that impact the progression of calcific aortic valve disease do not currently exist. New pathophysiological insights suggest that the processes leading to calcific aortic valve disease are metabolically active for many years before and during the clinical expression of disease. The identification of genetic and potentially causal mediators of calcific aortic valve disease allows opportunities for therapies that may slow progression to the point where aortic valve replacement can be avoided. Recent studies suggest that approximately one-third of aortic stenosis cases are associated with highly elevated lipoprotein(a) [Lp(a)] and pathways related to the metabolism of procalcifying oxidized phospholipids. Oxidized phospholipids can be carried by Lp(a) into valve leaflets but can also be formed in situ from cell membranes, lipoproteins, and apoptotic cells. This review will summarize the clinical data implicating the potential causality of Lp(a)/oxidized phospholipids, describe emerging therapeutic agents, and propose clinical trial designs to test the hypothesis that lowering Lp(a) will reduce progression aortic stenosis and the need for aortic valve replacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881 · cited 1×
“7% in subjects ≥75 years old, using data from several well-characterized cohorts of >28 000 subjects undergoing echocardiography.(67)”
Method2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Otto, C. M., Burwash, I. G., Legget, M. E., Munt, B. I., Fujioka, M., Healy, N. L., Kraft, C. D., Miyake-Hull, C. Y., & Schwaegler, R. G. (1997) · Circulation · doi:10.1161/01.cir.95.9.2262 · Cited by 1,146
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146
A Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137 · cited 12×
“On the basis of recent epidemiological data, an entry Lp(a) level >60 mg/dL, which will result in median levels 90 to 100 mg/dL in the trial based on epidemiological prevalence data from laboratory databases,71 appears to be most appropriate based on current knowledge of risk thresholds.19,46 However, this area is in…”
BackgroundInfluentialSelf-citationGenetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Rajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O'Brien, K. D., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.006767 · Cited by 842 · cited 1×
“405 Calcific aortic valve disease is a prevalent disorder that affects patients starting at middle age, with the incidence accelerating rapidly as individuals age beyond >80 years old.(1,2) It is estimated that >4.”
BackgroundCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Carabello, B. A., & Paulus, W. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60211-7 · Cited by 818
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815 · cited 1×
“In the ASTRONOMER trial (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin), which randomized patients to rosuvastatin 40 mg daily versus placebo, rosuvastatin showed no differences in echocardiographically determined annualized progression rate by peak aortic jet velocity (V peak ).(12) In a…”
MethodViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754 · cited 3×
“This approach has been subsequently translated to humans in 3 trials.(62,63) Following a successful phase 1 study in volunteers using IONIS-APO(a) Rx ,(62) a phase 2 study in subjects with highly elevated Lp(a) levels (1 group with Lp(a) 50–175 mg/dL and a second group with >175 mg/dL) showed a mean 72% reduction in L…”
BackgroundMethodSelf-citationBurgess, S., Ference, B. A., Staley, J. R., Freitag, D. F., Mason, A. M., Nielsen, S. F., Willeit, P., Young, R., Surendran, P., Karthikeyan, S., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1470 · Cited by 689 · cited 1×
“These modest reductions in Lp(a) are unlikely to be of sufficient robustness to impact the disease process, particularly in patients who may need >50% reduction in Lp(a) levels.(56,57) Traditional drug therapies generally include small molecules that inhibit enzyme activity or receptor function, such as HMG-CoA reduct…”
BackgroundElevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595 · cited 2×
“On the basis of recent epidemiological data, an entry Lp(a) level >60 mg/dL, which will result in median levels 90 to 100 mg/dL in the trial based on epidemiological prevalence data from laboratory databases,(71) appears to be most appropriate based on current knowledge of risk thresholds.(19,46) However, this area is…”
BackgroundTsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Self-citationGenesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques
Hutcheson, J. D., Goettsch, C., Bertazzo, S., Maldonado, N., Ruiz, J. L., Goh, W., Yabusaki, K., Faits, T., Bouten, C., Franck, G., et al. (2016) · Nature Materials · doi:10.1038/nmat4519 · Cited by 419
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.020 · Cited by 417
Self-citationInnate sensing of oxidation-specific epitopes in health and disease
Binder, C. J., Papac-Milicevic, N., & Witztum, J. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.63 · Cited by 403 · cited 1×
“Lipoproteins such as LDL and very LDL (VLDL) can passively diffuse through endothelial surfaces via concentration gradients, accumulate in subendothelial spaces, become oxidized, promote inflammation, and mediate atherogenesis.(31) In a similar way, Lp(a) may permeate through vascular endothelium and provide a substra…”
BackgroundArsenault, B. J., Boekholdt, S. M., Dubé, M.-P., Rhéaume, É., Wareham, N. J., Khaw, K.-T., Sandhu, M. S., & Tardif, J.-C. (2014) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000400 · Cited by 315
Dweck, M. R., Jenkins, W. S. A., Vesey, A. T., Pringle, M. A. H., Chin, C. W. L., Malley, T. S., Cowie, W. J. A., Tsampasian, V., Richardson, H., Fletcher, A., et al. (2014) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.113.001508 · Cited by 260
Schlotter, F., Halu, A., Goto, S., Blaser, M. C., Body, S. C., Lee, L. H., Higashi, H., DeLaughter, D. M., Hutcheson, J. D., Vyas, P., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032291 · Cited by 256
Smith, J. G., Luk, K., Schulz, C.-A., Engert, J. C., Do, R., Hindy, G., Rukh, G., Dufresne, L., Almgren, P., Owens, D. S., et al. (2014) · JAMA · doi:10.1001/jama.2014.13959 · Cited by 238
Merki, E., Graham, M. J., Mullick, A. E., Miller, E. R., Crooke, R. M., Pitas, R. E., Witztum, J. L., & Tsimikas, S. (2008) · Circulation · doi:10.1161/circulationaha.108.786822 · Cited by 156
Self-citationYeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1206 · Cited by 136
Thériault, S., Gaudreault, N., Lamontagne, M., Rosa, M., Boulanger, M.-C., Messika-Zeitoun, D., Clavel, M.-A., Capoulade, R., Dagenais, F., Pibarot, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03260-6 · Cited by 135 · cited 1×
“More recently, a gene in the vicinity of rs7543130, possibly the PALMD gene, which expresses a protein localized predominantly in actin filaments, has also been implicated in GWAS (Genome-Wide Association Studies) studies as a potential causal mediator.(24,25)”
BackgroundGenome-wide analysis yields new loci associating with aortic valve stenosis
Helgadottir, A., Thorleifsson, G., Gretarsdottir, S., Stefansson, O. A., Tragante, V., Thorolfsdottir, R. B., Jonsdottir, I., Bjornsson, T., Steinthorsdottir, V., Verweij, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03252-6 · Cited by 125
Merki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124 · cited 1×
“Further refinements were made by specifically targeting of apo(a) mRNA in transgenic Lp(a) mice.(61)”
BackgroundSelf-citationRomanoski, C. E., Che, N., Yin, F., Mai, N., Pouldar, D., Civelek, M., Pan, C., Lee, S., Vakili, L., Yang, W.-P., et al. (2011) · Circulation Research · doi:10.1161/circresaha.111.241869 · Cited by 115
Dichtl, W., Alber, H. F., Feuchtner, G. M., Hintringer, F., Reinthaler, M., Bartel, T., Süssenbacher, A., Grander, W., Ulmer, H., Pachinger, O., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.060 · Cited by 108
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Parish, S., Hopewell, J. C., Hill, M. R., Marcovina, S., Valdes-Marquez, E., Haynes, R., Offer, A., Pedersen, T. R., Baigent, C., Collins, R., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.117.001696 · Cited by 93 · cited 1×
“These modest reductions in Lp(a) are unlikely to be of sufficient robustness to impact the disease process, particularly in patients who may need >50% reduction in Lp(a) levels.(56,57) Traditional drug therapies generally include small molecules that inhibit enzyme activity or receptor function, such as HMG-CoA reduct…”
Background
Cited by
The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
An update on lipid oxidation and inflammation in cardiovascular diseases
Zhong, S., Li, L., Shen, X., Li, Q., Xu, W., Wang, X., Tao, Y., & Yin, H. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.03.036 · Cited by 332
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease
Han, D., Zhou, T., Li, L., Ma, Y., Chen, S., Yang, C., Ma, N., Song, M., Zhang, S., Wu, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065213 · Cited by 38
“48 Thus, the identification of novel potential therapeutic targets for treating CAVD is urgently needed.”
Background
Metadata
- Authors
- Tsimikas, S.
- Venue
- Circulation Research
- Published
- 2019-02
- Volume
- 124
- Issue
- 3
- Pages
- 405-415
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2911965953
- Cited by
- 85
- References
- 31
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.